## **Amendments to the Claims**

1. (Currently Amended). A compound having a formula I,

$$Z \xrightarrow{A_3} Y \xrightarrow{R^1} A_2 \xrightarrow{(R^3)_r} E_1 \xrightarrow{E_2} A_1 \xrightarrow{Q}$$

$$E_3 \xrightarrow{E_4} E_5$$

$$E_4 \xrightarrow{R^4} R^5$$

or a pharmaceutically acceptable <u>salt salt, solvate, hydrate or stereoisomer</u> thereof, wherein:

 $A_1$  is:  $CH_2$ , O or S;

A<sub>2</sub> and A<sub>3</sub> are independently: CH<sub>2</sub>, O or S;

 $E_1$ ,  $E_2$ ,  $E_3$ ,  $E_4$  and  $E_5$  are each CH or substituted carbon bearing  $A_2$  or and  $R^3$ ; or at least one of  $E_1$ ,  $E_2$ ,  $E_3$ ,  $E_4$  and  $E_5$  is nitrogen and each of others being CH or substituted carbon bearing  $A_2$  or and  $R^3$ ;

Q is:  $-C(O)OR^6$ ;

Y is: a bond or  $C_1$ - $C_6$  alkyl;

Z is: a) phenyl-T-pyridinyl or naphthyl-T-pyridinyl each optionally substituted with one or more R<sup>7</sup>; wherein T is a single bond, C, C=O, or O;;

n is: 1, 2, 3, 4, 5 or 6

p is: 1 or 2;

 $R^1$  and  $R^2$  are each independently:

Serial No.: 10/566291 Docket No.: X-15998 hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, and; R<sup>3</sup> is: hydrogen, nitro, <del>cyano,</del> hydroxyl, halo, or <del>haloalkyl,</del> haloalkyloxy, aryloxy,  $C_1$ - $C_6$  alkyl $\frac{1}{27}$ C1-C6-alkoxy, or C<sub>3</sub>-C<sub>8</sub>-cycloalkyl; R<sup>4</sup> and R<sup>5</sup> are each hydrogen; R<sup>6</sup> is: hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl or aminoalkyl;

R<sup>7</sup> is: hydrogen,

<del>oxo,</del>

nitro,

<del>cyano,</del>

hydroxyl,

halo,

haloalkyl,

haloalkyloxy,

aryloxy,

<del>arylalkyl,</del>

```
aminoalkyl,

C<sub>1</sub>-C<sub>6</sub> alkyl, or

C<sub>1</sub>-C<sub>6</sub> alkoxy;

(CH<sub>2</sub>)<sub>n</sub>C<sub>2</sub>-C<sub>8</sub> eycloalkyl,

C(O)R<sup>9</sup>;

C(O)OR<sup>9</sup>;

C(=NOR<sup>8</sup>)R<sup>9</sup>;

CR<sup>8</sup>(OH)R<sup>9</sup>;

C[=C(R<sup>8</sup>)<sub>2</sub>]R<sup>9</sup>;

OR<sup>9</sup>;

SR<sup>9</sup>-or

S(O)<sub>p</sub>R<sup>9</sup>;
```

```
R^{9} is: \quad \text{hydrogen or $C_{4}$-$C_{6}$-alkyl; and} \\ R^{9} is: \quad \text{hydrogen,} \\ C_{4}$-$C_{6}$-alkyl,} \\ C_{3}$-$C_{8}$-cycloalkyl,} \\ aryl,} \\ \text{heteroaryl or} \\ \text{heterocyclyl,} \\ \text{wherein alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl being optionally} \\ \text{substituted with one or more substituents selected from the group consisting of:} \\ \text{hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy,} \\ \text{oxo, $C_{4}$-$C_{6}$-alkyl, $C_{4}$-$C_{6}$-alkoxy and $C_{2}$-$C_{8}$-cycloalkyl.} \\ \end{cases}
```

2. (Currently Amended). The compound of Claim 1, wherein the compound is represented by a compound of formula II,

$$Z \xrightarrow{Q} Y \xrightarrow{R^1 \quad R^2 \quad (R^3)_r} A_1 \xrightarrow{Q} A_1 \xrightarrow{Q} II$$

or a pharmaceutically acceptable <u>salt</u> <u>salt</u>, <u>solvate</u>, <u>hydrate or stereoisomer</u> thereof, wherein:

 $A_1$  is:  $CH_2$ , O or S;

A<sub>2</sub> is: O or S or CH<sub>2</sub>;

Q is:  $-C(O)OR^6$ ;

Y is: a bond or  $C_1$ - $C_6$  alkyl;

Z is: phenyl-T-pyridinyl or naphthyl-T-pyridinyl each optionally substituted with one or more  $R^7$ ; wherein T is a single bond, C <u>. C=O</u>, or O;;

n is: 1, 2, 3, 4, 5 or 6

p is: 1 or 2;

R<sup>1</sup> and R<sup>2</sup> are each independently:

hydrogen,

C<sub>1</sub>-C<sub>6</sub> alkyl

;

R<sup>3</sup> is: hydrogen,

nitro,

<del>cyano,</del>

hydroxyl,

halo, or

haloalkyl,

```
haloalkyloxy,
           aryloxy,
           C_1-C_6-alkyl,
          C<sub>1</sub>-C<sub>6</sub>-alkoxy_or
          C<sub>3</sub>-C<sub>8</sub>-cycloalkyl;
R<sup>4</sup> and R<sup>5</sup> are each hydrogen;
R<sup>6</sup> is: hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl or aminoalkyl;
R<sup>7</sup> is: hydrogen,
           <del>oxo,</del>
           nitro,
          <del>cyano,</del>
          hydroxyl,
          halo,
          haloalkyl,
          haloalkyloxy,
          aryloxy,
          arylalkyl,
          aminoalkyl,
          C<sub>1</sub>-C<sub>6</sub> alkyl,
          C_1-C_6 alkoxy;
          (CH<sub>2</sub>)<sub>n</sub>C<sub>3</sub>-C<sub>8</sub> eycloalkyl,
          C(O)R^9
          C(O)OR^9
          C(=NOR^8)R^9
          CR^8(OH)R^9
          C[=C(R^8)_2]R^9
           OR^9
          SR<sup>9</sup>-or
```

$$S(O)_p R^9$$
;

R<sup>8</sup> is: hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl; and

R<sup>9</sup>is: hydrogen,

 $C_1$ - $C_6$ -alkyl,

C<sub>3</sub>-C<sub>8</sub> cycloalkyl,


aryl,

heteroaryl or

heterocyclyl,

wherein alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of: hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy and C<sub>3</sub>-C<sub>8</sub> cycloalkyl.

3. (Currently Amended). The compound of Claim 2, wherein Z is an optionally substituted structural formula selected from following:



wherein T is:

a bond

; and

rings g and h are each optionally substituted with one or more groups independently selected from the group consisting of:

hydrogen, oxo, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, arylalkyl, aminoalkyl,  $S(O)_2R^9$ ,  $C_1$ - $C_6$  alkyl, and  $C_1$ - $C_6$  alkoxy-and  $(CH_2)_nC_3$ - $C_8$  eycloalkyl.

4. (Canceled)

(Withdrawn). The compound of Claim 2, wherein the compound 5. is represented by structural formula IV,

$$\begin{array}{c|c} R^3 \\ \hline \\ b \\ \hline \\ C \\ \hline \\ C \\ \hline \\ C \\ \hline \\ IV \\ \end{array}$$

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:  $A_1$  and  $A_2$  are respectively:

O and O,

CH<sub>2</sub> and O,

CH<sub>2</sub> and S,

O and S or

S and O;

m is: 1 or 2;

 $R^1$  is:  $C_1$ - $C_3$  alkyl;

R<sup>3</sup> is: hydrogen, halo or C<sub>1</sub>-C<sub>6</sub> alkyl;

R<sup>6</sup> and R<sup>9</sup> are each independently: hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl;

T is: a bond, -O-, -C(O)-, -S(O)- $-S(O)_2$ -,  $-C(=CH_2)$ -, -C(=NOH)- or -CH(OH)-; and rings b and c are each optionally substituted with one or more groups independently selected from:

hydrogen, oxo, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, arylalkyl, aminoalkyl,  $S(O)_2R^9$ ,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy and  $(CH_2)_nC_3$ - $C_8$ cycloalkyl.

6. (Withdrawn). The compound of Claim 5, wherein the compound is represented by structural formula V,

$$R^{1}$$
 $COOH$ 
 $COOH$ 
 $COOH$ 
 $COOH$ 

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

T is: a bond, -O- or -C(O)-;

R<sup>1</sup> is: methyl, ethyl or cyclopropyl;

R<sup>3</sup> is: methyl or ethyl; and

rings b and c are each optionally substituted with one or more substituent independently selected from the group consisting of: hydrogen, Cl, Br,  $CF_3$ ,  $OCF_3$ , methyl, ethyl, isopropyl,  $N(CH_3)_2$ ,  $S(O)_2CH_3$ , methoxy and cyclopropyl.

7. (Withdrawn). The compound of Claim 6, wherein the compound is represented by a structural formula VI,

$$\begin{array}{c} \text{CH}_3 \\ \text{COOH} \\ \end{array}$$

or a pharmaceutically acceptable salt, solvate or hydrate thereof.

- 8. (Canceled)
- 9. (Canceled)

Serial No.: 10/566291

10. (Currently amended). The compound of Claim 2, wherein the compound is represented by structural formula VIII,

Docket No.: X-15998

$$R^3$$
 $R^1$ 
 $COOR^6$ 
 $CH_2)_m$ 
 $A_2$ 

VIII

or a pharmaceutically acceptable <u>salt salt, solvate, hydrate or stereoisomer</u> thereof, wherein:

 $A_1$  and  $A_2$  are respectively:

O and O,

CH<sub>2</sub> and O,

CH<sub>2</sub> and S,

O and S or

S and O;

m is: 1 or 2;

 $R^1$  is:  $C_1$ - $C_3$  alkyl; and

R<sup>3</sup> is: hydrogen, halo or C<sub>1</sub>-C<sub>6</sub> alkyl;

R<sup>6</sup> and R<sup>9</sup> are each independently: hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl;

T is: a bond or -O-, and

ring b is optionally substituted with one or more groups independently selected from: hydrogen, oxo, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, arylalkyl, aminoalkyl, S(O)<sub>2</sub>R<sup>9</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl, and C<sub>1</sub>-C<sub>6</sub> alkoxy-and (CH<sub>2</sub>)<sub>a</sub>C<sub>3</sub>-C<sub>8</sub> cycloalkyl.

11. (Currently Amended). The compound of Claim 10, wherein the compound is represented by structural formula IX,

Serial No.: 10/566291

$$R^3$$
COOH

IX

Docket No.: X-15998

or a pharmaceutically acceptable <u>salt</u> <u>salt</u>, <u>solvate</u>, <u>hydrate or stereoisomer</u> thereof, wherein:

 $R^1$  is  $C_1$ - $C_3$  alkyl;

R<sup>3</sup> is: hydrogen, halo or C<sub>1</sub>-C<sub>4</sub> alkyl;

ring b is optionally substituted with one or more groups independently selected from the group consisting of: hydrogen, halo, haloalkyl, haloalkyloxy and C<sub>1</sub>-C<sub>6</sub> alkyl.

12. (Currently Amended). The compound of Claim 11, wherein the compound is represented by structural formula X,

$$CF_3 \xrightarrow{N} CH_3 COOH$$

or a pharmaceutically acceptable salt salt, solvate or hydrate thereof.

13. (Previously Presented). The compound of Claim 11, wherein the compound is represented by structural formula XI,

$$H_3C$$
 $CH_3$ 
 $COOH$ 
 $XI$ 

14. (Withdrawn). The compound of Claim 2, wherein the compound is represented by structural formula XII,

$$\begin{array}{c|c} & & & & R^3 \\ \hline & & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ &$$

XII

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:  $A_1$  and  $A_2$  are respectively:

O and O,

CH<sub>2</sub> and O,

CH<sub>2</sub> and S,

O and S or

S and O;

m is: 1 or 2;

 $R^1$  is:  $C_1$ - $C_3$  alkyl; and

R<sup>3</sup> is: hydrogen, halo or C<sub>1</sub>-C<sub>6</sub> alkyl;

 $R^4$ ,  $R^5$ ,  $R^6$  and  $R^9$  are each independently: hydrogen or  $C_1$ - $C_6$  alkyl;

rings k and l are each optionally substituted with one or more groups independently selected from:

hydrogen, oxo, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, arylalkyl, aminoalkyl,  $S(O)_2R^9$ ,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy and  $(CH_2)_nC_3$ - $C_8$  cycloalkyl.

# 15. (Canceled)

16. (Currently Amended). The compound of Claim 2, wherein the compound is represented by structural formula XIII,

#### XIII

or a pharmaceutically acceptable <u>salt</u> <u>salt</u>, <u>solvate</u>, <u>hydrate or stereoisomer</u>-thereof, wherein

m is 1, 2, 3, or 4.

## 17. (Canceled).

18. (Withdrawn). The compound of Claim 16, wherein the compound is represented by structural formula XV,

$$R^{2}$$
 $T$ 
 $COOH$ 

## XV

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

T is: a bond, O or C(O);

R<sup>2</sup> is: methyl, ethyl or cyclopropyl;

R<sup>3</sup> is: methyl or ethyl; and

rings b and c are each optionally substituted with one or more substituent independently selected from the group consisting of: hydrogen, Cl, Br, CF<sub>3</sub>, OCF<sub>3</sub>, N(CH<sub>3</sub>)<sub>2</sub>, S(O)<sub>2</sub>CH<sub>3</sub>, methyl, ethyl, isopropyl, methoxy and cyclopropyl.

19. (Currently Amended). The compound of Claim 2, wherein the compound is represented by structural formula XVI,

#### XVI

or a pharmaceutically acceptable <u>salt</u> <u>salt</u>, <u>solvate</u>, <u>hydrate or stereoisomer</u> thereof, wherein Y is a branched alkyl.

- 20. (Canceled).
- 21. (Withdrawn). The compound of Claim 19, wherein the compound structural formula XVIII,

COOH
$$C = \begin{pmatrix} R^3 \\ C \\ R^{9a} \\ R^{9b} \end{pmatrix}$$

XVIII

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

T is: a bond, O or C(O);

R<sup>3</sup> is: methyl or ethyl;

 $R^{9a}$  and  $R^{9b}$  are each independently hydrogen, methyl or ethyl, wherein at least one of  $R^{9a}$  and  $R^{9b}$  being methyl or ethyl;

rings b and c are each optionally substituted with one or more substituent independently selected from the group consisting of: hydrogen, Cl, Br, CF<sub>3</sub>, OCF<sub>3</sub>, S(O)<sub>2</sub>CH<sub>3</sub>, N(CH<sub>3</sub>)<sub>2</sub>, methyl, ethyl, isopropyl, methoxy and cyclopropyl.

- 22. (Canceled).
- 23. (Withdrawn). The compound of Claim 1, wherein the compound is a compound of formula XX,

$$Z \xrightarrow{Q} Y \xrightarrow{R^1} A_2 \xrightarrow{(R^3)_r} A_1 \xrightarrow{Q} XX$$

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

A<sub>1</sub> is: a bond, CH<sub>2</sub>, O or S, and wherein A<sub>1</sub> and R<sup>4</sup> or A<sub>1</sub> and R<sup>5</sup> together being a 3- to 6-membered carbocyclyl when A<sub>1</sub> is a carbon;

A<sub>2</sub> is: O or S or CH<sub>2</sub>;

Q is:  $-C(O)OR^6$ , or  $R^{6A}$ ;

Y is: a bond,  $C_1$ - $C_6$  alkyl or  $C_3$ - $C_6$  cycloalkyl;

- Z is: a) aryl;
  - b) a 5- to 10-membered heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S,
  - c) bi-aryl, wherein biaryl being defined as aryl substituted with another aryl or aryl substituted with heteroaryl, or

d) bi-heteroaryl, wherein bi-heteroaryl being defined as heteroaryl substituted with another heteroaryl, or heteroaryl substituted with aryl, and wherein aryl, heteroaryl, bi-aryl and bi-heteroaryl being optionally substituted with one or more groups independently selected from R<sup>7</sup>;

```
n is: 1, 2, 3, 4, 5 or 6

p is: 1 or 2;

r is: 1, 2, 3, or 4;

R^1 and R^2 are each independently:

hydrogen,

haloalkyl,

C_1-C_6 alkyl,

(CH_2)_nC_3-C_8 cycloalkyl, or
```

 $R^1$  and  $R^2$  form a 4- to 8-membered nonaromatic carbocyclic ring; and wherein at least one of  $R^1$  and  $R^2$  is alkyl or cycloalkyl, and;

```
R<sup>3</sup> is: hydrogen,
nitro,
cyano,
hydroxyl,
halo,
haloalkyl,
haloalkyloxy,
aryloxy,
C<sub>1</sub>-C<sub>6</sub> alkyl,
C<sub>1</sub>-C<sub>6</sub> alkoxy, or
C<sub>3</sub>-C<sub>8</sub> cycloalkyl;
```

R<sup>4</sup> and R<sup>5</sup> are each independently: hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl;

R<sup>6</sup> is: hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl or aminoalkyl;

R<sup>6A</sup> is: carboxamide, sulfonamide, acylsulfonamide, tetrazole,

R<sup>7</sup> is: hydrogen,

oxo,

nitro,

cyano,

hydroxyl,

halo,

haloalkyl,

haloalkyloxy,

aryloxy,

arylalkyl,

aminoalkyl,

 $C_1$ - $C_6$  alkyl,

C<sub>1</sub>-C<sub>6</sub> alkoxy,

 $(CH_2)_nC_3$ - $C_8$  cycloalkyl,

 $C(O)R^9$ ,

 $C(O)OR^9$ ,

 $C(=NOR^8)R^9$ ,

 $CR^8(OH)R^9$ ,

$$C[=C(R^8)_2]R^9$$
,  
 $OR^9$ ,  
 $SR^9$  or  
 $S(O)_pR^9$ ;

R<sup>8</sup> is: hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl; and

 $R^9$  is: hydrogen,  $C_1\text{-}C_6 \text{ alkyl},$   $C_3\text{-}C_8 \text{ cycloalkyl},$  aryl, heteroaryl or

heterocyclyl,

wherein alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl being optionally

substituted with one or more substituents selected from the group consisting of:

hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy and  $C_3$ - $C_8$  cycloalkyl.

24. (Canceled).

25. (Canceled).

26. (Withdrawn). The compound of Claim 23, wherein the compound is a compound of structural formula XXII,

$$R^{1}$$
 $COOH$ 
 $COOH$ 
 $COOH$ 
 $COOH$ 
 $COOH$ 

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

T is: a bond, -O- or -C(O)-;

R<sup>1</sup> is: methyl, ethyl or cyclopropyl;

R<sup>3</sup> is: methyl or ethyl; and

rings b and c are each optionally substituted with one or more substituent independently selected from the group consisting of: hydrogen, Cl, Br, CF<sub>3</sub>, OCF<sub>3</sub>, S(O)<sub>2</sub>CH<sub>3</sub>, N(CH<sub>3</sub>)<sub>2</sub>, methyl, ethyl, isopropyl, methoxy and cyclopropyl.

27. (Withdrawn). The compound of Claim 1, wherein the compound is a compound of structural formula XXIII,

$$\begin{array}{c} R^{1} \\ \downarrow \\ COOR^{6} \\ \downarrow \\ CH_{2})_{m} \\ A_{2} \\ \downarrow \\ N \end{array}$$

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:  $A_1$  and  $A_2$  are respectively:

O and O,

CH<sub>2</sub> and O,

CH<sub>2</sub> and S,

O and S or

S and O;

m is: 1, 2, 3 or 4;

 $R^1$  is:  $C_1$ - $C_3$  alkyl; and

 $R^3$  is: hydrogen, halo or  $C_1$ - $C_6$  alkyl;

R<sup>6</sup> and R<sup>9</sup> are each independently: hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl;

T is: a bond, -O-, -C(O)-, -S(O) –S(O)<sub>2</sub>-, -C(=CH<sub>2</sub>)-, -C(=NOH)- or -CH(OH)-; and rings b and c are each optionally substituted with one or more groups independently selected from:

hydrogen, oxo, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, arylalkyl, aminoalkyl,  $S(O)_2R^9$ ,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy and  $(CH_2)_nC_3$ - $C_8$  cycloalkyl.

- 28. (Canceled).
- 29. (Currently Amended). A compound of Claim 1 selected from the group consisting of:

	Q	\
	Structure	<u>Name</u>
29	H <sub>3</sub> C CH <sub>3</sub> O CH <sub>3</sub> O OH	3-{4-[3-(3-Benzoyl-5-ethyl-pyridin-2-yloxy)-butoxy]-2-methyl-phenyl}-propionic acid
30	H <sub>3</sub> C CH <sub>3</sub> OCH <sub>3</sub> OCH	{4-[3-(3-Benzoyl-5-ethyl-pyridin-2-yloxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
31	Chiral  CH <sub>3</sub> OH	3-{4-[3-(3-Benzoyl-5-chloro-pyridin-2-yloxy)-butoxy]-2-methyl-phenyl}-propionic acid
32	CI—CH <sub>3</sub> OH	{4-[3-(3-Benzoyl-5-chloro-pyridin-2-yloxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid

33	Chiral	2 (1 52 (2 - 1 5
	<i>κ</i> \	3-{4-[3-(3-Benzoyl-5-
		trifluoromethyl-pyridin-2-
	_ CH <sub>3</sub>	yloxy)-butoxy]-2-methyl-
	F °	phenyl}-propionic acid
	F CH <sub>3</sub>	
	OH .	
34	Chiral	{4-[3-(3-Benzoyl-5-
		trifluoromethyl-pyridin-2-
	F, /=\CH <sub>3</sub>	yloxy)-butoxy]-2-methyl-
		phenylsulfanyl}-acetic acid
	F H <sub>3</sub> C OH	
35	Chiral	3-{4-[3-(5-Chloro-3-
	<b>&gt;</b> _/	phenoxy-pyridin-2-yloxy)-
		butoxy]-2-methyl-phenyl}-
	CI—CH <sub>3</sub>	propionic acid
	CH <sub>3</sub> OH	
36	Chiral	3-{4-[3-(5-Chloro-3-
	<u>\</u> \	phenoxy-pyridin-2-yloxy)-
	о′ сн <sub>з</sub>	butoxy]-2-ethyl-phenyl}-
	ci—( )	propionic acid
	CH <sub>3</sub>	
37	Chiral	{4-[3-(5-Chloro-3-
		phenoxy-pyridin-2-yloxy)-
	CH <sub>3</sub>	butoxy]-2-methyl-
		phenylsulfanyl}-acetic acid
	N H₃C OH	

	Structure	<u>Name</u>
38	F CH <sub>3</sub> Chiral OH	3-{2-Methyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid
39	Chiral  Chiral  Chiral	3-{2-Ethyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid
40	Chiral  Chiral  CH <sub>3</sub> CH <sub>3</sub> OH	3-{2-Ethyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid
41	F OH CH <sub>3</sub>	3-{2-Methyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-propoxy]-phenyl}-propionic acid (trifluoroacetic acid salt)
42	F OH CI CH <sub>3</sub>	3-{4-[3-(5-Chloro-3-phenoxy-pyridin-2-yloxy)-propoxy]-2-methyl-phenyl}-propionic acid

	Structure	<u>Name</u>
43	CI————————————————————————————————————	3-{4-[2-(5-Chloro-3-phenoxy-pyridin-2-ylamino)-ethoxy]-2-methyl-phenyl}-propionic acid
44	H <sub>3</sub> C CH <sub>3</sub>	3-{4-[3-(3-Benzoyl-5-ethyl-pyridin-2-yloxy)-propoxy]-2-methyl-phenyl}-propionic acid
45	Chiral  H <sub>3</sub> C  O  OH	3-{2-Methyl-4-[3-(6-methyl-2-phenoxy-pyridin-3-yloxy)-butoxy]-phenyl}-propionic acid
49	Chiral  H <sub>3</sub> C  OH  OH	3-{4-[3-(4-Ethyl-2-pyridin-2-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
50	H <sub>3</sub> C OH	{4-[3-(4-Ethyl-2-pyridin-2-yl-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid

	Structure	<u>Name</u>
51	CH <sub>3</sub> Chiral OH	3-{2-Ethyl-4-[3-(4-ethyl-2-pyridin-2-yl-phenoxy)-butoxy]-phenyl}-propionic acid
52	CI————————————————————————————————————	3-{4-[3-(4-Chloro-2-pyridin-2-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
53	F CH <sub>3</sub> O Chiral	3-{2-Methyl-4-[3-(2-pyridin-2-yl-4-trifluoromethyl-phenoxy)-butoxy]-phenyl}-propionic acid
54	F H <sub>3</sub> C Chiral OH	3-{2-Ethyl-4-[3-(2-pyridin-2-yl-4-trifluoromethyl-phenoxy)-butoxy]-phenyl}-propionic acid
55	Chiral CH <sub>3</sub> C O O O O O O O O O O O O O O O O O O O	3-{4-[3-(4-Ethyl-2-pyridin-3-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
56	CI—CH <sub>3</sub> OH	3-{4-[3-(4-Chloro-2-pyridin-3-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid

	Structure	<u>Name</u>
57	H <sub>3</sub> C Chiral	3-{4-[3-(4-Ethyl-2-pyridin-4-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
58	F Chiral Chiral OH	3-{2-Methyl-4-[3-(2-pyridin-4-yl-4-trifluoromethyl-phenoxy)-butoxy]-phenyl}-propionic acid
59	F H <sub>3</sub> C Chiral OH	3-{2-Ethyl-4-[3-(2-pyridin-4-yl-4-trifluoromethyl-phenoxy)-butoxy]-phenyl}-propionic acid
90	H <sub>3</sub> C CH <sub>3</sub> O OH	3-{4-[3-(3-Benzoyl-5-ethyl-pyridin-2-yloxy)-butoxy]-2-methyl-phenyl}-propionic acid
91	H <sub>3</sub> C CH <sub>3</sub> OH	{4-[3-(3-Benzoyl-5-ethyl-pyridin-2-yloxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid

	Structure	<u>Name</u>
92	Chiral	3-{4-[3-(3-Benzoyl-5-
		chloro-pyridin-2-yloxy)-
	CH₃	butoxy]-2-methyl-phenyl}-
		propionic acid
	CH <sub>3</sub>	
93	Chiral	{4-[3-(3-Benzoyl-5-chloro-
		pyridin-2-yloxy)-butoxy]-2-
	CH₃	methyl-phenylsulfanyl}-
		acetic acid
	CH <sub>3</sub>	
94	Chiral	3-{4-[3-(3-Benzoyl-5-
		trifluoromethyl-pyridin-2-
	о ,сн,	yloxy)-butoxy]-2-methyl-
	F O O O O	phenyl}-propionic acid
	F CH <sub>3</sub> OH	
95	Chiral	{4-[3-(3-Benzoyl-5-
		trifluoromethyl-pyridin-2-
		yloxy)-butoxy]-2-methyl-
	F CH <sub>3</sub> O CH <sub>3</sub> O O O	phenylsulfanyl}-acetic acid
96	Chiral	3-{4-[3-(5-Chloro-3-
		phenoxy-pyridin-2-yloxy)-
	√=CH₃	butoxy]-2-methyl-phenyl}-
		propionic acid
	CH <sub>3</sub> OH	

	Structure	<u>Name</u>
97	Chiral	3-{4-[3-(5-Chloro-3-
		phenoxy-pyridin-2-yloxy)-
	CH₃	butoxy]-2-ethyl-phenyl}-
	CI—CI—CI—O	propionic acid
	CH <sub>3</sub>	
98	Chiral	{4-[3-(5-Chloro-3-
	<b>&gt;</b>	phenoxy-pyridin-2-yloxy)-
	CH <sub>3</sub>	butoxy]-2-methyl-
	$CI \longrightarrow O \longrightarrow O \longrightarrow S \longrightarrow O$	phenylsulfanyl}-acetic acid
	он	
99	F CH <sub>3</sub> Chiral	3-{2-Methyl-4-[3-(3-
	F F	phenoxy-5-trifluoromethyl-
	OH OH	pyridin-2-yloxy)-butoxy]-
		phenyl}-propionic acid
100	Chiral	3-{2-Ethyl-4-[3-(3-
	<b>&gt;</b>	phenoxy-5-trifluoromethyl-
	F. CH <sub>3</sub>	pyridin-2-yloxy)-butoxy]-
	F N O N O	phenyl}-propionic acid
	H₃C OH	
101	Chiral	3-{2-Ethyl-4-[3-(3-
		phenoxy-5-trifluoromethyl-
	F, CH <sub>3</sub>	pyridin-2-yloxy)-butoxy]-
	F N H <sub>3</sub> C	phenyl}-propionic acid
	ОН	

	Structure	<u>Name</u>
102	F OH	3-{2-Methyl-4-[3-(3-phenoxy-5-trifluoromethyl-
	F N O CH <sub>3</sub>	pyridin-2-yloxy)-propoxy]- phenyl}-propionic acid (trifluoroacetic acid salt)
103	F OH CI CH <sub>3</sub>	3-{4-[3-(5-Chloro-3-phenoxy-pyridin-2-yloxy)-propoxy]-2-methyl-phenyl}-propionic acid
104	CI—NOH	3-{4-[2-(5-Chloro-3-phenoxy-pyridin-2-ylamino)-ethoxy]-2-methyl-phenyl}-propionic acid
105	H <sub>3</sub> C CH <sub>3</sub> O OH	3-{4-[3-(3-Benzoyl-5-ethyl-pyridin-2-yloxy)-propoxy]-2-methyl-phenyl}-propionic acid
106	H <sub>3</sub> C OH	3-{2-Methyl-4-[3-(6-methyl-2-phenoxy-pyridin-3-yloxy)-butoxy]-phenyl}-propionic acid

	Structure	<u>Name</u>
110	Chiral	3-{4-[3-(4-Ethyl-2-pyridin-
	) N	2-yl-phenoxy)-butoxy]-2-
	H <sub>3</sub> C CH <sub>3</sub>	methyl-phenyl}-propionic
	H <sub>3</sub> C OH	acid
111	Chiral	{4-[3-(4-Ethyl-2-pyridin-2-
	N CH3 O	yl-phenoxy)-butoxy]-2-
	H <sub>3</sub> C OH	methyl-phenylsulfanyl}-
		acetic acid
112	H <sub>3</sub> C  CH <sub>3</sub> Chiral	2 (2 Ed1 4 E2 (4 -d. 1 2
112	CH <sub>3</sub> O Cillia	3-{2-Ethyl-4-[3-(4-ethyl-2-
	NOH	pyridin-2-yl-phenoxy)-
		butoxy]-phenyl}-propionic
	CH <sub>3</sub>	acid
113	Chiral	3-{4-[3-(4-Chloro-2-
	>= <sub>N</sub>	pyridin-2-yl-phenoxy)-
	CI—CH <sub>3</sub>	butoxy]-2-methyl-phenyl}-
	H <sub>3</sub> C	propionic acid
	о́н	
114	F CH <sub>3</sub> O	3-{2-Methyl-4-[3-(2-
	F OH	pyridin-2-yl-4-
		trifluoromethyl-phenoxy)-
	ĈH₃	butoxy]-phenyl}-propionic
		acid
115	F Chiral	3-{2-Ethyl-4-[3-(2-pyridin-
	F OH	2-yl-4-trifluoromethyl-
		phenoxy)-butoxy]-phenyl}-
	CH₃	propionic acid

	Structure	<u>Name</u>
116	Chiral	3-{4-[3-(4-Ethyl-2-pyridin-
	H <sub>3</sub> C, CH <sub>2</sub>	3-yl-phenoxy)-butoxy]-2-
	H <sub>3</sub> C CH <sub>3</sub>	methyl-phenyl}-propionic
	H <sub>3</sub> C O	acid
	`он	
117	Chiral	3-{4-[3-(4-Chloro-2-
	CH <sub>3</sub>	pyridin-3-yl-phenoxy)-
	ci—(	butoxy]-2-methyl-phenyl}-
	CH₃ OH	propionic acid
118	N Chiral	3-{4-[3-(4-Ethyl-2-pyridin-
		4-yl-phenoxy)-butoxy]-2-
	H <sub>3</sub> C CH <sub>3</sub>	methyl-phenyl}-propionic
	H <sub>3</sub> C O	acid
	ОН	
119	F Chiral	3-{2-Methyl-4-[3-(2-
	Г Г ОН	pyridin-4-yl-4-
		trifluoromethyl-phenoxy)-
	CH <sub>3</sub>	butoxy]-phenyl}-propionic
	-	acid
120	F	3-{2-Ethyl-4-[3-(2-pyridin-
	F OH	4-yl-4-trifluoromethyl-
		phenoxy)-butoxy]-phenyl}-
	CH₃	propionic acid
141	Chiral	(R)-3-(4-{3-[4-ethyl-2-
	l i	(pyridine-2-carbonyl)-
	CH <sub>3</sub>	phenoxy]-butoxy}-2-
	H <sub>3</sub> C O O	methyl-phenyl)-propionic
	CH <sub>3</sub> OH	acid

Serial No.: 10/566291

	Structure	<u>Name</u>
175	Chiral CH <sub>3</sub> OH	(R)- 3-{4-[3-(4-chloro-2-pyridin-3-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid

30. (Withdrawn). The compound of Claim 29, wherein the compound is

Docket No.: X-15998

or a pharmaceutically acceptable salt, solvate or hydrate thereof.

- 31. (Currently Amended). A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Claim 1 or a pharmaceutically acceptable <u>salt salt</u>, solvate or hydrate thereof.
  - 32. (Canceled).
  - 33. (Canceled).
  - 34. (Canceled).
  - 35. (Canceled).
  - 36. (Canceled).
  - 37. (Canceled).
  - 38. (Canceled).
  - 39. (Canceled).
  - 40. (Canceled).
  - 41. (Canceled).
  - 42. (Canceled).

43. (Previously Presented). A method for lowering blood-glucose in a mammal in need thereof comprising the step of administering an effective amount of a compound of Claim 1.

- 44. (Canceled).
- 45. (Canceled).
- 46. (Canceled).
- 47. (Canceled).
- 48. (Canceled).
- 49. (Canceled)